Afinitor Tablet
NDC Package 0078-0620-51
Package Information
Afinitor (everolimus) tablets is everolimus is used to treat various types of cancer (such as kidney, breast, pancreas, lung, stomach/intestinal cancers). This formulation utilizes a tablet delivery system. Marketed by Novartis Pharmaceuticals Corporation, this product is identified by NDC 0078-0620 and is authorized under FDA application NDA022334.
Identification & Billing
- RxCUI: 1119400 - everolimus 7.5 MG Oral Tablet
- RxCUI: 1119402 - AFINITOR 7.5 MG Oral Tablet
- RxCUI: 1119402 - everolimus 7.5 MG Oral Tablet [Afinitor]
- RxCUI: 1119402 - Afinitor 7.5 MG Oral Tablet
- RxCUI: 1308428 - everolimus 2 MG Tablet for Oral Suspension
Clinical Specifications
- Cytochrome P450 2D6 Inhibitors - [MoA] (Mechanism of Action)
- Cytochrome P450 3A4 Inhibitors - [MoA] (Mechanism of Action)
- Decreased Immunologic Activity - [PE] (Physiologic Effect)
- Kinase Inhibitor - [EPC] (Established Pharmacologic Class)
- Protein Kinase Inhibitors - [MoA] (Mechanism of Action)
- mTOR Inhibitor Immunosuppressant - [EPC] (Established Pharmacologic Class)
- mTOR Inhibitors - [MoA] (Mechanism of Action)
Regulatory & Marketing
Hierarchy Structure
- 0078 - Novartis Pharmaceuticals Corporation
- 0078-0620 - Afinitor
- 0078-0620-51 - 28 BLISTER PACK in 1 CARTON / 1 TABLET in 1 BLISTER PACK (0078-0620-61)
- 0078-0620 - Afinitor
The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.
* Please review the full disclaimer at the bottom of this page.
Frequently Asked Questions
What is the distribution configuration for this product package?
The code 0078-0620-51 identifies a specific commercial package of 28 blister pack in 1 carton / 1 tablet in 1 blister pack (0078-0620-61) of Afinitor, a human prescription drug labeled by Novartis Pharmaceuticals Corporation. This product is billed for "EA" each discreet unit and contains an estimated amount of 28 billable units per package. This tablet is formulated for oral use and contains everolimus as the active substance.
Is this product currently listed with the FDA?
Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Novartis Pharmaceuticals Corporation on July 29, 2011. The current certification is valid through December 31, 2027.
What are the primary indications for this medication?
Everolimus is used to treat various types of cancer (such as kidney, breast, pancreas, lung, stomach/intestinal cancers). Everolimus is also used in people with a certain genetic disorder (tuberous sclerosis complex) to treat certain types of benign tumors in the brain or kidney. It works by slowing or stopping the growth of cancer or tumor cells.
How is this Novartis Pharmaceuticals Corporation product billed for insurance claims?
For medical billing and reimbursement, this package follows the 11-digit CMS format: 00078062051. Quantities are measured in per "each", products billed on a per each basis are usually products dispensed in discreet units.. There are 28 total billable units per package. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.
11-Digit Code Conversion
Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:
Note: The zero is added to the Labeler segment to maintain the 5-4-2 structure.